Long lasting drug formulations

• US 9,687,564 B2
• Filed: 10/16/2014
• Issued: 06/27/2017
• Est. Priority Date: 09/14/2006
• Status: Expired due to Fees

• Current Assignee: Medgenics Medical Israel Ltd.
• Original Assignee: Medgenics Medical Israel Ltd.
• Inventors: Stern, Baruch S., Pearlman, Andrew L.
• Primary Examiner(s): Ton, Thaian N
• Assistant Examiner(s): Montanari, David A
• Application Number:
  US14/516,544
• Publication Number:
  US 20150110743A1
• Time in Patent Office: 985 Days
• CPC Class Codes: A61K 31/70 Carbohydrates; Sugars; Derivatives thereof sorbitol A61K31/047
• CPC Class Codes: A61K 35/36 Skin; Hair; Nails; Sebaceous glands; Cerumen; Epidermis; Epithelial cells; Keratinocytes; Langerhans cells; Ectodermal cells islets of Langerhans A61K35/39
• CPC Class Codes: A61K 38/1816 Erythropoietin [EPO]
• CPC Class Codes: A61K 38/212 IFN-alpha
• CPC Class Codes: A61K 47/6901 Conjugates being cells, cell fragments, viruses, ghosts, red blood cells or viral vectors
• CPC Class Codes: A61K 48/0066 Manipulation of the nucleic acid to modify its expression pattern, e.g. enhance its duration of expression, achieved by the presence of particular introns in the delivered nucleic acid
• CPC Class Codes: A61K 48/0075 characterised by an aspect of the delivery route, e.g. oral, subcutaneous
• CPC Class Codes: A61K 48/0091 Purification or manufacturing processes for gene therapy compositions
• CPC Class Codes: A61P 7/06 Antianaemics
• CPC Class Codes: C07K 14/505 Erythropoietin [EPO]
• CPC Class Codes: C12N 15/86 Viral vectors
• CPC Class Codes: C12N 15/88 using microencapsulation, e.g. using amphiphile liposome vesicle
• CPC Class Codes: C12N 2710/10343 viral genome or elements thereof as genetic vector
• CPC Class Codes: C12N 7/00 Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00

Abstract

The present invention is directed to long-lasting erythropoietin therapeutic formulations and their methods of use wherein the formulation comprises a genetically modified micro-organ that comprises a vector which comprises a nucleic acid sequence operably linked to one or more regulatory sequences, wherein the nucleic acid sequence encodes erythropoietin.

Claims

1. A viral vector comprising a nucleic acid sequence encoding erythropoietin comprising a nucleotide sequence at least 95% homologous to SEQ ID NO:

1.

2. The viral vector of claim 1, wherein the viral vector is a helper-dependent adenoviral vector.

3. The viral vector of claim 1, wherein the viral vector is an adeno-associated viral vector.

4. The viral vector of claim 1, wherein the viral vector comprises at least one regulatory element comprising a SV40 polyadenylation sequence, a CAG promoter, and/or a CMV promoter.

5. The viral vector of claim 1, wherein the nucleic acid sequence comprises one or both of SEQ ID NO:

12 and SEQ ID NO;

13.

6. The viral vector of claim 1, wherein the nucleic acid sequence comprises SEQ ID NO:

1.